Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "4877", "attributes": { "award_id": "NNX11AG68G", "title": "The U.S. Antarctic Meteorite Program has been one of the most successful endeavors in the history of meteoritics and planetary science. Through the 2009-2010 field season, -19,700 meteorites have been recovered. These meteorites have produced fundamental", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-03", "end_date": "2017-06-30", "award_amount": 0, "principal_investigator": { "id": 16929, "first_name": "CATHERINE", "last_name": "CORRIGAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The U.S. Antarctic Meteorite Program has been one of the most successful endeavors in the history of meteoritics and planetary science. Through the 2009-2010 field season, -19,700 meteorites have been recovered. These meteorites have produced fundamental", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8097", "attributes": { "award_id": "75N92021C00003-P00002-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2023-01-31", "award_amount": 2500000, "principal_investigator": { "id": 23980, "first_name": "TODD", "last_name": "WOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Resubmission of Application 3136. This product concept has been updated to include Flu viral targets along with SARS-CoV-2. The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020. The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.", "keywords": [ "2019-nCoV", "Acute", "Biological Assay", "COVID-19 assay", "COVID-19 patient", "Clinical", "Communicable Diseases", "Computer software", "Coupled", "Detection", "Molecular", "Patients", "RADx Tech", "RNA Sequences", "Reporting", "Running", "Seasons", "Specimen", "Technology", "Time", "Update", "Viral", "Virus", "Virus Diseases", "base", "betacoronavirus", "flu", "instrument", "respiratory", "waiver" ], "approved": true } }, { "type": "Grant", "id": "7780", "attributes": { "award_id": "1ZIAMD000006-06", "title": "Understanding and reducing health disparities through social and behavioral research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 443383, "principal_investigator": { "id": 23586, "first_name": "Kelvin", "last_name": "Choi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Understanding inter-relationships between social determinants and tobacco use With the increase in e-cigarette use in the US, we examined whether e-cigarette use can reduce disparities in cigarette smoking in the US. We analyzed the Tobacco Use Supplement of the Current Population Survey (TUS-CPS) and found that the prevalence of daily e-cigarette use, a behavior that is associated with smoking cessation, is low in the US adult smoker population. Additionally, the prevalence is particularly low among non-Hispanic Blacks, suggesting the e-cigarettes may increase smoking disparities by race. In a different study, we analyzed the Population Assessment of Tobacco and Health (PATH) study data to examine the association between secondhand smoke exposure and subsequent academic performance among youth. We found that youth who were exposed to more secondhand smoke (measured by hours per week) had lower subsequent academic performance compared to those who were not exposed to secondhand smoke. This finding suggests that secondhand smoke exposure could influence academic performance, which I an important factor for enrolling in post-secondary education. Investigate mediating and moderating factors associated with tobacco use disparities We continue to examine how tobacco marketing influence tobacco use behaviors. We analyzed data from the Population Assessment of Tobacco and Health (PATH) study and found that exposure to e-cigarette marketing is associated with subsequent e-cigarette experimentation among youth and young adult. In a focus group study with a racial/ethnically diverse group of young adult smokers, we explored their perceptions related to smoking cessation treatments, and found that many of them expressed negative perceptions toward these treatments. These findings indicate the need to better communicate efficacy of these treatment and facilitate access to them among young adult smokers, especially those in racial/ethnic minority populations. In collaboration with the PATH Study team, we examined how harm perceptions of tobacco products changes over time and how they relate to tobacco use behaviors. We found that perceived tobacco products to be harm was associated with not using the product, but use of product was also associated with lower harm perception subsequently. This highlight the importance of matching health risk messages with tobacco use behaviors to prevent tobacco use vs. promote cessation. In a separate analysis, we worked with the PATH Study team to examine if e-cigarette and pharmacotherapy use among smokers attempting to quit smoking are associated with long-term smoking cessation. We found that e-cigarette use, nor pharmacotherapy, was associated with long-term smoking cessation. This provides evidence on whether e-cigarettes should be used for smoking cessation, and highlight the limited efficacy of the current pharmacotherapy for smoking cessation. Investigate the impact of tobacco use patterns and health outcomes Through a collaboration with extramural investigators, we examined the Youth Risk Behavioral Survey data and found that e-cigarette use was associated with asthma among youth, independent of cigarette and marijuana use. This provides additional evidence on the possible health impact of e-cigarette on youth respiratory health. COVID-19 and Tobacco Use We have developed a study to examine how COVID-19 impact adult tobacco users, and how they have modified their tobacco use behaviors accordingly. The study has complete internal review and is schedule to launch in late FY2020.", "keywords": [ "Address", "Adult", "Advertising", "Area", "Asthma", "Behavior", "Behavioral", "Behavioral Research", "COVID-19", "Cessation of life", "Characteristics", "Collaborations", "Complex", "Data", "Data Analyses", "Databases", "Economics", "Education", "Electronic cigarette", "Enrollment", "Epidemiology", "Exposure to", "Extramural Activities", "Focus Groups", "Goals", "Health", "Health Communication", "Health Personnel", "Hour", "Individual", "Intervention", "Marketing", "Measures", "Mediating", "Modeling", "Not Hispanic or Latino", "Outcome", "Pattern", "Perception", "Performance", "Pharmacotherapy", "Population", "Population Analysis", "Population Assessment of Tobacco and Health", "Prevalence", "Price", "Public Health", "Reporting", "Research", "Research Personnel", "Risk", "Schedule", "Secondary Schools", "Smoker", "Smoking", "Smoking Cessation Intervention", "Social Marketing", "Surgeon", "Surveys", "Time", "Tobacco Industry", "Tobacco use", "Treatment Efficacy", "Vision", "Work", "Youth", "behavioral health", "cigarette smoking", "demographics", "disadvantaged population", "disparity reduction", "electronic cigarette use", "environmental tobacco smoke", "environmental tobacco smoke exposure", "ethnic diversity", "ethnic minority population", "health disparity", "insight", "marijuana use", "mortality", "novel", "population based", "population health", "population survey", "racial and ethnic", "racial disparity", "reduce tobacco use", "respiratory health", "sleep quality", "smoking cessation", "smoking prevalence", "social", "social determinants", "social health determinants", "socioeconomics", "tobacco advertising", "tobacco control", "tobacco prevention", "tobacco products", "tobacco user", "young adult" ], "approved": true } }, { "type": "Grant", "id": "5006", "attributes": { "award_id": "NNX10AK05G", "title": "We request support from NASA for the overlapping open science meetings/conferences of the Global Land Project (GLP) and the Urbanization and Global Environment Change (UGEC) project to be held October 15-19, 20 I 0, on the campus of Arizona State Universi", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2010-03-04", "end_date": "2012-02-17", "award_amount": 0, "principal_investigator": { "id": 17954, "first_name": "BILLIE", "last_name": "TURNER", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "We request support from NASA for the overlapping open science meetings/conferences of the Global Land Project (GLP) and the Urbanization and Global Environment Change (UGEC) project to be held October 15-19, 20 I 0, on the campus of Arizona State Universi", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10496", "attributes": { "award_id": "75N93022C00049-0-9999-1", "title": "DIGITAL TOOLS AGAINST MISINFORMATION ABOUT INFECTIOUS DISEASE TREATMENTS AND VACCINES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-08", "end_date": "2023-08-07", "award_amount": 299993, "principal_investigator": { "id": 26503, "first_name": "KHAI", "last_name": "EDOUARD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.", "keywords": [ "2019-nCoV", "Basic Science", "COVID-19 vaccine", "Coronavirus", "Misinformation", "Vaccines", "combat", "digital", "infectious disease treatment", "tool" ], "approved": true } }, { "type": "Grant", "id": "9536", "attributes": { "award_id": "2030139", "title": "Compounding Crises: Facing Hurricane Season in the Era of COVID-19", "funder": null, "funder_divisions": [], "program_reference_codes": [ "CK090", "RND123" ], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 199890, "principal_investigator": null, "other_investigators": [], "awardee_organization": null, "abstract": "Test", "keywords": [ "covid", "research" ], "approved": true } }, { "type": "Grant", "id": "9299", "attributes": { "award_id": "75N92020C00033-P00001-9999-1", "title": "RADX TECH PROJECT #4554: UBIQUITOME SARS-COV-2 LAB TEST ACCURACY WITHIN REACH OF EVERY AMERICAN WITH LIBERTY16 MOBILE REAL TIME PCR", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-29", "end_date": "2021-09-28", "award_amount": 1760000, "principal_investigator": { "id": 25039, "first_name": "PAUL", "last_name": "PICKERING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Gold standard SARS-CoV-2 testing (100% specificity, 100% sensitivity) has been available in America February 4, 2020, through the FDA CDA real time PCR test, yet it is still not available to many Americans who need it. Recent attempts to make SARS-CoV-2 testing more accessible (e.g. Abbott & Quidel) has been plagued by low throughput (single sample at a time) and high false negatives. What is needed is the CDC’s FDA authorized gold standard real time PCR testing within reach of every American. We propose to engage in a rapid enhancement and scaling program for our commercial mobile Liberty16 system that will allow this fully mobile real time PCR device to exceed the throughput- based gold standard 96-well based workflows in centralized labs while offering the same low false negative levels (<5%) observed with the CDC test. Enhanced Functionality. We will fast-track implemetation of several planned features that substantially enhance the throughput and user interface of the exisiting Liberty16 system: (1) Implementation of multiplex capability enabling single-well detection of multiple targets. This increases sample capacity from 3 to 14 (plus controls) per run. (2) Implementation of software and minor hardware modifications that significantly reduce the run time from 40 minutes to 25 minutes or less. (3) Update the Liberty16 iPhone/iPad user interface to include (i) a barcode reader for sample identifier input; (ii) automated reporting of multiplexed assays. (4) Optimize a safe sample collection and preparation workflow for saliva, enabling setup completion in under 5 minutes and with minimal processing steps.", "keywords": [ "2019-nCoV", "American", "Americas", "Bar Codes", "COVID-19 testing", "Cellular Phone", "Centers for Disease Control and Prevention (U.S.)", "Computer software", "Detection", "Devices", "Gold", "Minor", "Modification", "Preparation", "RADx Tech", "Reader", "Reporting", "Running", "Saliva", "Sampling", "Specificity", "System", "Testing", "Time", "Update", "base", "multiplex assay", "programs", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "4446", "attributes": { "award_id": "NNX15AL42G", "title": "THE OBJECTIVES OF OUR PROPOSED WORK ARE, I. TO DERIVE SPATIAL AND TEMPORAL VARIATIONS OF TITAN''S SURFACE TEMPERATURE BY ANALYSIS OF THE MOON''S OUTGOING RADIANCE AROUND 19 M (530 CM 1); (II) TO COMPARE THE RESULTS TO PREDICTIONS FROM AN ATMOSPHERIC GENE", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2015-05-26", "end_date": "2017-05-25", "award_amount": 0, "principal_investigator": { "id": 15205, "first_name": "VALERIA", "last_name": "COTTINI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "THE OBJECTIVES OF OUR PROPOSED WORK ARE, I. TO DERIVE SPATIAL AND TEMPORAL VARIATIONS OF TITAN''S SURFACE TEMPERATURE BY ANALYSIS OF THE MOON''S OUTGOING RADIANCE AROUND 19 M (530 CM 1); (II) TO COMPARE THE RESULTS TO PREDICTIONS FROM AN ATMOSPHERIC GENE", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9169", "attributes": { "award_id": "75N92020C00015-P00001-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-28", "end_date": "2021-08-27", "award_amount": 24369230, "principal_investigator": { "id": 24932, "first_name": "STUART HELLYAR HELLYAR", "last_name": "HELLYAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A battery powered, POC/at home device for the quantitation and detection of SARS-CoV-2 simultaneously with Influenza A & B, with the accuracy, specificity and sensitivity equivalent to or better than the current CDC RT-PCR Lab based methodology.", "keywords": [ "COVID-19 detection", "Centers for Disease Control and Prevention (U.S.)", "Devices", "Home", "Influenza A virus", "Influenza B Virus", "Methodology", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Sensitivity and Specificity", "base", "programs" ], "approved": true } }, { "type": "Grant", "id": "8432", "attributes": { "award_id": "75N92021C00018-0-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 3700000, "principal_investigator": { "id": 22342, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1424, "count": 14236 } } }